[221 Pages Report] Revenue from the global cytomegalovirus treatment market currently stands at USD 228.8 Million in 2022. Rising at a CAGR of 6.1% (2022 to 2028), demand for cytomegalovirus treatment is predicted to reach a market valuation of USD 326 Million by the end of 2028.
| Attribute | Details |
|---|---|
| Global Cytomegalovirus Treatment Market Size (2022) | USD 228.8 Million |
| Net Revenue Estimation (2028) | USD 326 Million |
| Global Growth Rate (2022 to 2028) | 6.1% CAGR |
| Market Share of Hospital Pharmacies | 47.8% |
Cytomegalovirus treatment contributes 0.8% to the global infectious disease diagnostics market revenue. Increasing instances of viral infections and rising awareness of cytomegalovirus symptoms are expected to propel demand for cytomegalovirus treatment on a global level.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
| Particulars | Details |
|---|---|
| H1, 2021 | 6.10% |
| H1, 2022 Projected | 6.08% |
| H1, 2022 Outlook | 5.48% |
| BPS Change - H1, 2022 (O) - H1, 2022 (P) | (-) 60 ↓ |
| BPS Change - H1, 2022 (O) - H1, 2021 | (-) 62 ↓ |
The comparative analysis and market growth rate of global cytomegalovirus treatment market as studied by Future Market Insights, will show a negative BPS growth in H1-2022 outlook as compared to H1-2022 projected period by 60 BPS. A decline in BPS growth is expected in H1-2022 over H1- 2021 duration with 62 Basis Point Share (BPS).
The market for cytomegalovirus treatment is subject to changes as per the macro and industrial standards in relevance to stringent regulations in biopharmaceuticals development and production and licensing.
The market observes a decline in the BPS values owed to the inefficacy of the therapy in patients with severe immunosuppression or disseminated disease. With the rising cases of such incidences after the global coronavirus pandemic, the limitations for cytomegalovirus treatment posed a negative impact upon the market growth, thus resulting in the dropped BPS values.
Conversely, with the recent FDA approval of the first drug for adults and paediatric patients with cytomegalovirus infections and diseases which cannot be managed with the current available antiviral treatment methods in 2022, has paved way for the market to observe a positive outlook towards growth over the forecasted years.
The key development in the market includes the adoption of oral antivirals such as ganciclovir for the management of cytomegalovirus in immunocompromised patients.
The world has seen substantial rise in viral infections and other infectious diseases, and this has propelled demand for better diagnostic and treatment solutions. The cytomegalovirus treatment market exhibited expansion at a CAGR of 5.7% from 2013 to 2021.
Increasing prevalence of congenital CMV infections, rising awareness about cytomegalovirus symptoms, increasing spending on research & development activities, rising clinical trials and studies for CMV infections, etc., are major trends that will guide cytomegalovirus treatment demand through 2028.
The risk of reactivation of cytomegalovirus infections in multiple individuals has been observed and this is one of the areas of prime focus for many cytomegalovirus treatment providers. The use of antiviral agents that have very low risks associated with them is seeing high demand in the development of antiviral drugs for cytomegalovirus diseases. Antiviral agents such as ganciclovir and valganciclovir are expected to see a rise in popularity over the forecast period.
Risks and side effects associated with antiviral drugs for cytomegalovirus diseases are anticipated to restrain market potential to a certain extent over the forecast period. The cytomegalovirus treatment industry is projected to rise at a steady CAGR of 6.1% from 2022 to 2028.
Principal Consultant
Increasing Focus on Development of CMV Vaccines
Awareness of cytomegalovirus symptoms is being raised across the world by multiple initiatives taken by governments and non-profit organizations to bolster public safety. Clinical trials are being carried out to boost the development of novel cytomegalovirus treatment.
Risks of Antiviral Drugs for Cytomegalovirus Diseases Could Adversely Impact Market Growth
Very little is known about CMV infections, and this has proven to be a major obstacle to cytomegalovirus diagnosis and cytomegalovirus testing. Increasing demand for cytomegalovirus natural treatment is also expected to constrain the adoption of antiviral drugs for cytomegalovirus diseases.
These factors are expected to have a hindering effect on global cytomegalovirus treatment device demand through 2028.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
High R&D Activity in North America to Boost Cytomegalovirus Diagnosis
Detailed assessment of market stance across regions such as North America, Latin America, Europe, East Asia, South Asia & Pacific, and the Middle East & Africa (MEA) has been profiled in this revised FMI market analysis.
Demand for cytomegalovirus treatment products in North America is anticipated to hold a major market share in the global marketplace over the forecast. The presence of major cytomegalovirus treatment providers and rapid advancements in cytomegalovirus diagnosis and cytomegalovirus treatment are expected to shape market potential.
Rising prevalence of congenital CMV infections, increasing use of combinational antiviral therapies, and increasing awareness of cytomegalovirus treatment in stem cell transplants are expected to be major trends in the Europe cytomegalovirus treatment market over the forecast period.
Increasing investments in research & development activities, rising healthcare expenditure, and increasing popularity of cytomegalovirus natural treatment are major factors that influence cytomegalovirus treatment demand in South Asia and East Asia. Rising focus on boosting cytomegalovirus testing in these regions is expected to majorly favour market potential.
Increasing Focus on Healthcare & Rising Awareness about Cytomegalovirus Symptoms in India
The healthcare infrastructure in India is rapidly changing and the focus on health and hygiene has fostered a new wave of demand for better diagnostic and treatment solutions in the nation. Government initiatives are boosting awareness about viral infections and are further bolstering awareness about cytomegalovirus symptoms in India.
High population, increasing prevalence of HIV infections, high birthrate, etc., are some of the major factors that influence cytomegalovirus treatment market potential in India. Cytomegalovirus diagnosis and cytomegalovirus testing are expected to increase in India as awareness about cytomegalovirus symptoms increases through 2028.
High Research Activity to Explore Cytomegalovirus Pathology to Boost Market Potential
The USA is known for its well-established healthcare infrastructure, and this has made it a highly lucrative market for the healthcare industry. Cytomegalovirus treatment providers are expected to further advance their research & development activities to provide better cytomegalovirus diagnosis and treatment.
Rising research for cytomegalovirus testing, increasing investments from government and non-profit research organizations, and rising availability of cytomegalovirus diagnosis procedures are expected to be major factors influencing cytomegalovirus treatment market potential through 2028.
Hospital Pharmacies to Hold Dominant Market Share
In 2022, hospital pharmacies account for 46.8% of the global cytomegalovirus treatment industry landscape. With most cytomegalovirus diagnosis procedures being accessible only through professional subscriptions, this has boosted their sales via hospital pharmacies, which are more accessible to patients and are recommended by professionals.
Other distribution channels such as retail pharmacies and e-Commerce currently hold market shares of 36.7% and 16.4%, respectively, in 2022, in the global cytomegalovirus treatment space.
Cytomegalovirus treatment providers are investing in the research & development of innovative and more effective treatments for CMV infections.
| Attribute | Details |
|---|---|
| Forecast Period | 2022 to 2028 |
| Historical Data Available for | 2013 to 2021 |
| Market Analysis | USD million for Value |
| Key Regions Covered | North America; Latin America; Europe; East Asia; South Asia & Pacific; Middle East & Africa (MEA) |
| Key Countries Covered | United States, Canada, Brazil, Mexico, Germany, UK, France, Spain, Italy, China, Japan, South Korea, India, Indonesia, Malaysia, Singapore, Australia, New Zealand, Turkey, South Africa, and GCC Countries |
| Key Market Segments Covered | Drug Type, Application, Distribution Channel, Region |
| Key Companies Profiled | Chimerix Inc.; Thermo Fisher Scientific; Abbot; Becton Dickinson and Company; Pfizer Inc.; Merck & Company Inc.; Mylan N.V.; Johnson & Johnson; Bio-Rad Laboratories Inc.; F. Hoffmann-La Roche Ltd. |
| Pricing | Available upon Request |
Demand for cytomegalovirus treatment is predicted to increase at a CAGR of 6.1% from 2022 to 2028.
The global cytomegalovirus treatment market stands at a net worth USD 228.8 million in 2022.
By 2028, the global cytomegalovirus treatment market is anticipated to attain a valuation of USD 326 million.
Prime market players such as Chimerix Inc., Thermo Fisher Scientific, Abbot, Becton Dickinson and Company, Pfizer Inc., Merck & Company Inc., Mylan N.V., Johnson & Johnson, and Bio-Rad Laboratories Inc. have been profiled in this market survey.
At present, hospital pharmacies account for a dominant share of 46.8% in the global cytomegalovirus treatment industry.
1. Executive Summary 2. Market Introduction 3. Market Background 4. Market Dynamics 5. Cytomegalovirus Treatment Market: Key Inclusions 6. North America Cytomegalovirus Treatment Market Analysis 2013 to 2021 and Opportunity Assessment 2022 to 2028 7. Western Europe Cytomegalovirus Treatment Market Analysis 2013 to 2021 and Opportunity Assessment 2022 to 2028 8. Eastern Europe Cytomegalovirus Treatment Market Analysis 2013 to 2021 and Opportunity Assessment 2022 to 2028 9. Latin America Cytomegalovirus Treatment Market Analysis 2013 to 2021 and Opportunity Assessment 2022 to 2028 10. Asia Pacific excluding China (APEC) Cytomegalovirus Treatment Market Analysis 2013 to 2021 and Opportunity Assessment 2022 to 2028 11. China Cytomegalovirus Treatment Market Analysis 2013 to 2021 and Opportunity Assessment 2022 to 2028 12. MEA Cytomegalovirus Treatment Market Analysis 2013 to 2021 and Opportunity Assessment 2022 to 2028 13. Forecast Factors: Relevance and Impact 14. Competition Analysis 14.1. Merck & Co. Inc. 14.2. Mylan N.V. 14.3. Chimerix, Inc. 14.4. Thermo Fisher Scientific 14.5. Abbott 14.6. Becton, Dickinson and Company 14.7. Johnson & Johnson 14.8. Bio-Rad Laboratories, Inc. 14.9. F. Hoffmann-La Roche Ltd 14.10. Pfizer 15. Global Cytomegalovirus Treatment Market Analysis 2013 to 2021 and Opportunity Assessment 2022 to 2028, By Region 15.1. North America 15.2. Western Europe 15.3. Eastern Europe 15.4. Latin America 15.5. Asia Pacific excluding China 15.6. China 15.7. Middle East and Africa 16. Global Cytomegalovirus Treatment Market Analysis 2013 to 2021 and Opportunity Assessment 2022 to 2028, By Drug Type 16.1. Ganciclovir 16.2. Valganciclovir 16.3. Foscarnet 16.4. Cidofovir 16.5. Others 17. Global Cytomegalovirus Treatment Market Analysis 2013 to 2021 and Opportunity Assessment 2022 to 2028, By Application 17.1. Stem Cell Transplantation 17.2. Organ Transplantation 17.3. Congenital CMV infection 17.4. Others 18. Global Cytomegalovirus Treatment Market Analysis 2013 to 2021 and Opportunity Assessment 2022 to 2028, By Distribution Channel 18.1. Hospital pharmacies 18.2. Retail Pharmacies 18.3. E-commerce 19. Global Cytomegalovirus Treatment Market Analysis 2013 to 2021 and Opportunity Assessment 2022 to 2028 20. Assumptions and Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
Cytomegalovirus Treatment Market
